EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks

Camille Lupianez-Merly, Saam Dilmaghani, Kia Vosoughi, Michael Camilleri iD

Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (4) · 475-491

DOI: 10.1111/apt.17856 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 02.01.2024. Verfasst von Camille Lupianez-Merly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rocheste…. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Liver Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 144 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements.

Aims

To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA‐approved and upcoming anti‐obesity medications (AOMs).

Methods

We conducted a comprehensive review in PubMed for articles on pathophysiology and complications of obesity, including terms ‘neurohormonal’, ‘obesity’, ‘incretin’, and ‘weight loss’. Next, we searched for clinical trial data of all FDA‐approved AOMs, including both the generic and trade names of orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and semaglutide. Additional searches were conducted for tirzepatide and retatrutide ‐ medications expecting regulatory approval. Searches included combinations of terms related to mechanism of action, indications, side effects, risks, and future directions.

Results

We reviewed the pathophysiology of obesity, including specific role of incretins and glucagon. Clinical data supporting the use of various FDA‐approved medications for weight loss are presented, including placebo‐controlled or, when available, head‐to‐head trials. Beneficial metabolic effects, including impact on liver disease, adverse effects and risks of medications are discussed, including altered gastrointestinal motility and risk for periprocedural aspiration.

Conclusion

AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction‐associated steatotic liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsLiver DiseasesHumansIncretinsTopiramateFructoseObesityWeight Loss

Stichwörter der Autor:innen

aspirationgastric emptyingincretinsliraglutidenausearetatrutidesemaglutide

Substanzen

IncretinsTopiramateFructoseAnti-Obesity Agents

Autor:innen und Institutionen

  • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Michael Camilleri

Zitieren

APA

Lupianez-Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024). Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks. Alimentary Pharmacology & Therapeutics, 59(4), 475-491. https://doi.org/10.1111/apt.17856

Vancouver

Lupianez-Merly C, Dilmaghani S, Vosoughi K, Camilleri M. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks. Alimentary Pharmacology & Therapeutics. 2024;59(4):475-491. doi:10.1111/apt.17856

BibTeX
@article{LupianezMerly2024,
  author = {Lupianez-Merly, Camille and Dilmaghani, Saam and Vosoughi, Kia and Camilleri, Michael},
  title = {Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {4},
  pages = {475--491},
  doi = {10.1111/apt.17856}
}
Kostenlos starten →